<DOC>
	<DOCNO>NCT00885495</DOCNO>
	<brief_summary>This phase I , open-label , controlled drug interaction study determine effect darunavir plus ritonavir pharmacokinetics hydroxymethylglutaryl coenzyme A ( HMG-CoA ) reductase inhibitor , rosuvastatin , HIV-1-seronegative subject .</brief_summary>
	<brief_title>Darunavir/Ritonavir Rosuvastatin Pharmacokinetic Study</brief_title>
	<detailed_description>Twelve HIV-negative healthy volunteer randomize one two group . Group 1 would receive rosuvastatin 10mg daily ( Treatment A ) interval 1 7 day , follow washout period least 7 day . In interval 2 , darunavir/ritonavir 600/100mg bid ( Treatment B ) would administer 7 day , follow another 7 day washout period . Lastly , interval 3 subject administer darunavir/ritonavir rosuvastatin ( Treatment C ) total 7 day . Group 2 administer Treatment B interval 1 7 day , follow washout period 7 day , treatment A interval 2 7 day follow another 7 day washout period . Group 2 would co-administer rosuvastatin darunavir/ritonavir last 7 day . Intensive PK sampling perform day 7 , 21 35 follow meal .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Absence HIV1/HIV2 infection document licensed ELISA test kit within 21 day prior study entry . 2 . Male female subject , age ≥ 18 ≤ 60 year 3 . Weight ≥50 kg Body Mass Index ( [ BMI ] , weight kg divide square height meter ) ≥18.0 ≤ 35.0 kg/m2 . Refer Appendix I . 4 . Informed Consent Form ( ICF ) sign voluntarily first trialrelated activity . 5 . Able comply protocol requirement . 6 . Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , vital sign , result blood test urinalysis carry screen . 1 . History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use , investigator 's opinion would compromise subject 's safety and/or compliance trial procedure . 2 . Currently active significant gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease , opinion investigator would represent contraindication study enrollment . 3 . Creatinine clearance ≤ 60mL/min . 4 . Currently significant diarrhea , gastric stasis , constipation investigator 's opinion could influence drug absorption bioavailability . 5. eruption , drug allergy , food allergy , dermatitis , eczema , psoriasis , urticaria , opinion investigator would represent contraindication study enrollment . 6 . Previously demonstrate clinically significant allergy hypersensitivity excipients medication administer trial . 7 . History significant drug allergy , limited , sulphonamides penicillin . Prezista sulphonamide . The potential crosssensitivity drug sulphonamide class Prezista HIVnegative subject unknown . 8 . Use concomitant medication , include investigational , prescription , overthecounter product dietary supplement follow exception : aspirin , acetaminophen , antihistamine diphenhydramine , inhaler asthma , daily multivitamin , mineral supplement hormonal oral contraceptive . Concomitant medication list must discontinue least 7 day study entry . 9 . Female subject childbearing potential without use effective nonhormonal birth control method , willing continue practice birth control method least 30 day end treatment period ; Note : Estrogenbased hormonal contraception may reliable take Prezista , therefore eligible trial , woman childbearing potential either : use double barrier method prevent pregnancy ( i.e. , use condom either diaphragm cervical cap ) ; use nonestrogen hormonal base contraceptive combination barrier contraceptive ( i.e. , male condom , diaphragm cervical cap , female condom ) ; use intrauterine device combination barrier contraceptive ( i.e. , male condom , diaphragm cervical cap , female condom ) ; sexually active , vasectomized partner ( confirm sterile ) . Women tubal ligation require use one nonhormonal contraceptive method . Women postmenopausal least 2 year , woman total hysterectomy consider nonchildbearing potential . 10 . A positive pregnancy test breast feed screen . 11 . Participation investigational drug trial within 90 day prior first intake trial medication . 12 . Donation blood plasma within 60 day precede first trialrelated blood draw . 13 . Subjects follow laboratory abnormality screen defined Division AIDS Table Grading Severity Adult Pediatric Adverse Events ( `` DAIDS grading table '' ) accordance normal range trial clinical laboratory : serum creatinine grade 1 great ( ≥ 1.1 x upper limit laboratory normal range [ ULN ] ) ; lipase pancreatic amylase grade 1 great ( ≥ 1.1 x ULN ) ; hemoglobin grade 1 great ( ≤ 10.9 g/dL ) platelet count grade 1 great ( ≤ 124.999 x 109/L ) ; absolute neutrophil count grade 1 great ( ≤ 1.3 x 109/L ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) grade 1 great ( ≥ 1.25 x ULN ) ; total bilirubin grade 1 great ( ≥ 1.1 x ULN ) , laboratory abnormality grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>statin</keyword>
	<keyword>protease inhibitor</keyword>
</DOC>